Managing Toxicities and Supportive Care in Multiple Myeloma

In this segment, Dr. Noopur Raje asks Dr. Surbhi Sidana to discuss key considerations in managing acute and delayed toxicities associated with newer therapies in relapsed and refractory multiple myeloma. Dr. Sidana highlights that as treatment options expand, clinicians must be increasingly attentive to both short-term and long-term safety profiles. The discussion focuses on the importance of early recognition and management of treatment-related adverse events, including hematologic toxicities, infections, and immune-mediated effects. Dr. Sidana also emphasizes the role of proactive supportive care strategies, including monitoring, patient education, and multidisciplinary coordination, to help mitigate risks and maintain treatment continuity. The conversation underscores how effective toxicity management not only improves patient safety but also contributes to better long-term outcomes. This segment highlights the critical role of supportive care in optimizing treatment success in multiple myeloma.